Abstract:Elevated expression of eIF4E leads to widescale changes in alternative splicing in the absence of splice‐factor mutations. Aberrant splicing is typically attributed to splice‐factor (SF) mutation and contributes to malignancies including acute myeloid leukemia (AML). Here, we discovered a mutation‐independent means to extensively reprogram alternative splicing (AS). We showed that the dysregulated expression of eukaryotic translation initiation factor eIF4E elevated selective splice‐factor production, thereby impacting multiple spliceosome complexes, including factors mutated in AML such as SF3B1 and U2AF1. These changes generated a splicing landscape that predominantly supported altered splice‐site selection for ~800 transcripts in cell lines and ~4,600 transcripts in specimens from high‐eIF4E AML patients otherwise harboring no known SF mutations. Nuclear RNA immunoprecipitations, export assays, polysome analyses, and mutational studies together revealed that eIF4E primarily increased SF production via its nuclear RNA export activity. By contrast, eIF4E dysregulation did not induce known SF mutations or alter spliceosome number. eIF4E interacted with the spliceosome and some pre‐mRNAs, suggesting its direct involvement in specific splicing events. eIF4E induced simultaneous effects on numerous SF proteins, resulting in a much larger range of splicing alterations than in the case of mutation or dysregulation of individual SFs and providing a novel paradigm for splicing control and dysregulation.

Aberrations in Translation Initiation and Associated Diseases: From theeIF3a Perspective

Aberration in Translation Initiation and Associated Diseases: Role of the Eukaryotic Translation Initiation Factor 3A.

Eukaryotic Translation Initiation Factor 3 and Tumor

Eif3 Regulation of Protein Synthesis, Tumorigenesis, and Therapeutic Response.

Eukaryotic translation initiation factors and cancer.

Research progress on eIF3 a and cancer

Eukaryotic Translation Initiation Factors and Tumor

The Biological Roles Of Translation Initiation Factor 3b

Translation initiation factors and abnormalities of translation control in tumors

The eukaryotic translation initiation factor eIF4E reprograms alternative splicing

eIF3a: A new anticancer drug target in the eIF family.

Translational Regulator Eif2α in Tumor

Expression and Functional Roles of Eukaryotic Initiation Factor 4A Family Proteins in Human Cancers

Recent research progress of eIF3 in biological function

Translational control gone awry: a new mechanism of tumorigenesis and novel targets of cancer treatments.

The progress of protein synthesis factors eIFs, eEFs and eRFs in inflammatory bowel disease and colorectal cancer pathogenesis

Perturbations in eIF3 subunit stoichiometry alter expression of ribosomal proteins and key components of the MAPK signaling pathways.

eIF3i regulation of protein synthesis, cell proliferation, cell cycle progression, and tumorigenesis

Eukaryotic translation initiation factor 4A1 in the pathogenesis and treatment of cancers

Overexpression of Eif3e is Correlated with Colon Tumor Development and Poor Prognosis.

Molecular mechanisms of eukaryotic translation fidelity and their associations with diseases